HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $15 Price Target

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Immix Biopharma (NASDAQ: IMMX) and maintained a price target of $15 for the company's stock.